White-coat hypertension: Growing evidence in favour of its adverse prognostic significance

Journal of Hypertension

Volumn 35, Issue 4, 2017, Pages 710-712

  Mancia, Giuseppe ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ALL CAUSE MORTALITY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE EXACERBATION; DYSLIPIDEMIA; EDITORIAL; FOLLOW UP; GLUCOSE INTOLERANCE; HUMAN; METABOLIC DISORDER; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; WHITE COAT HYPERTENSION; BLOOD PRESSURE MEASUREMENT; HYPERTENSION; PROGNOSIS;

BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; HUMANS; HYPERTENSION; PROGNOSIS; WHITE COAT HYPERTENSION;

EID: 85042463441     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001289     Document Type: Editorial

References (22)

1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
2. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: A meta-Analysis. J Hypertens 2007; 25:2193-2198.
3. Pierdomenico SD, Lapenna D, Di Mascio R, Cuccurullo F. Short-And long-Term risk of cardiovascular events in white-coat hypertension. J Hum Hypertens 2008; 22:408-414.
4. Briasoulis A, Androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: A meta-Analysis. J Hypertens 2016; 34:593-599.
5. Huang Y, Huang W, Mai W, Cai X, An D, Liu Z, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens 2017; 35:677-688.
6. Mancia G. Clinical significance of white-coat hypertension. J Hypertens 2016; 34:623-626.
7. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, et al. Long-Term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54:226-232.
8. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Grassi G, Sega R. Increased long-Term risk of new-onset diabetes mellitus in white-coat and masked hypertension. J Hypertens 2009; 27:1672-1678.
9. Mancia G, Facchetti R, Grassi G, Bombelli M. Adverse prognostic value of persistent office blood pressure elevation in white coat hypertension. Hypertension 2015; 66:437-444.
10. Mancia G, Bombelli M, Brambilla G, Facchetti R, Sega R, Toso E, Grassi G. Long-Term prognostic value of white coat hypertension: An insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension 2013; 62:168-174.
11. Franklin SS, Thijs L, Asayama K, Li Y, Hansen TW, Boggia J, et al., IDACO Investigators. The cardiovascular risk of white-coat hypertension. J Am Coll Cardiol 2016; 68:2033-2043.
12. Franklin SS, Thijs L, Hansen TW, Li Y, Boggia J, Kikuya M, et al., International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Significance of white-coat hypertension in older persons with isolated systolic hypertension: A meta-Analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension 2012; 59:564-571.
13. Mancia G, Grassi G. The heterogeneous nature of white-coat hypertension. J Am Coll Cardiol 2016; 68:2044-2046.
14. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-Treated patients: A population-based study in Italy. J Hypertens 2008; 26:819-824.
15. Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: A critical reappraisal. Circ Res 2015; 116:1058-1073.
16. Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-Term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47:846-853.
17. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 2005; 111:1777-1783.
18. Myers MG. Statistical analysis as a cause of white-coat hypertension. J Hypertens 2017; 35:707-709.
19. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res 2015; 116:1034-1045.
20. Mancia G, Facchetti R, Parati G, Zanchetti A. Effect of long-Term antihypertensive treatment on white-coat hypertension. Hypertension 2014; 64:1388-1398.
21. Fagard RH, Staessen JA, Thijs L, Gasowski J, Bulpitt CJ, Clement D, et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Circulation 2000; 102: 1139-1144.
22. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.